(Q41711755)

7 October 2017

1 reference

title

New antiplatelet drugs (English)

1 reference

7 October 2017

Joseph JE

1

1 reference

7 October 2017

Machin SJ

series ordinal

2

1 reference

7 October 2017

publication date

1 December 1997

1 reference

7 October 2017

1 reference

7 October 2017

volume

11

1 reference

7 October 2017

issue

4

1 reference

7 October 2017

page(s)

178-190

1 reference

History of drugs for thrombotic disease. Discovery, development, and directions for the future

7 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Antiplatelet drugs. A comparative review

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Inhibition of platelet prostaglandin synthetase by oral aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Epinephrine potentiation of in viw stimuli reverses aspirin inhibition of platelet thrombos formation in stenosed canine coronary arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Thromboxane synthetase inhibition as antithrombotic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Randomized trial of a selective inhibitor of thromboxane A2 synthetase, (E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151), for prevention of restenosis after coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Pharmacokinetics of a new thromboxane A2 receptor antagonist, S-1452, and its effect on platelet aggregation in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Safety and efficacy of picotamide, a dual anti-thromboxane agent, in patients with thrombocytosis and a previous thromboembolic event: a 1-year observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

A dose-effect study of beraprost sodium in intermittent claudication

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Hemodynamic, platelet and clinical responses to prostacyclin in unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Prostacyclin infusion in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

The effect of taprostene in patients with acute myocardial infarction treated with thrombolytic therapy: results of the START study. Saruplase Taprostene Acute Reocclusion Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

1 reference

7 January 2021

Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

The basic pharmacology of ticlopidine and clopidogrel

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Long-term effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Thrombolytic action of ticlopidine: possible mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Ticlopidine in unstable angina. A more expensive aspirin?

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Ticlopidine Treatment Reduces the Progression of Nonproliferative Diabetic Retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Aplastic anemia associated with ticlopidine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Ticlopidine and fatal aplastic anemia in an elderly woman

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Thrombotic thrombocytopenic purpura related to ticlopidine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Ticlopidine and thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

1 reference

7 January 2021

Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp--specific adhesion receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

In search of a superaspirin for the heart

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Preventing restenosis with fish oils following coronary angioplasty. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

A meta-analysis of randomized trials of fish oil in prevention of restenosis following coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

A placebo-controlled, double-blind study of eicosapentaenoic acid-rich fish oil in patients with stable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

Antiplatelet agents in the prevention and therapy of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0268-960X%2897%2990018-7

7 January 2021

10.1016/S0268-960X(97)90018-7

Identifiers

DOI

1 reference

7 October 2017

1 reference